Dual-Energy Ablation • Real-Time Durability

The only catheter that delivers RF, PFA, and the evidence either one worked.

100% specificity for durable PFA lesion prediction, first-in-human, published in Europace. AblaView® is the first catheter to confirm lesion formation during the procedure, not at the three-month remap. RF and PFA in a single device.

Explore the Technology See the Evidence

Why AblaView®

Three things no one else can do.

The dual-energy durability gap is the largest unsolved problem in EP ablation. AblaView® is the only platform that closes it.

RF + PFA

Dual-Energy, Single Catheter

No other platform offers both modalities in one catheter. Switch energy mode per-lesion based on tissue, contact, and risk.

100%

FIM Specificity, Durable PFA

Specificity for durable PFA lesion prediction at three-month follow-up. First-in-human study, peer-reviewed in Europace, February 2025.

Gap Detection

Before the 3-Month Remap

Optical detection of preserved tissue between lesions, the precursor to reconnections. Independent of electrical signals biased by PFA stunning.

The Enabling Mechanism

PS-OCT: seeing what electricity can't.

Polarization-Sensitive Optical Coherence Tomography measures tissue birefringence directly, with 10µm axial resolution. That is 100x higher than intracardiac ultrasound. The physics is what makes real-time durability and gap detection possible.

10µm

Axial Resolution

1310nm swept-source laser, 50 kHz A-scan. Resolves individual tissue layers.

< 50ms

Photon to Prediction

The Clinical AI Engine runs on NVIDIA IGX Orin with deterministic latency for closed-loop safety.

860+

Ablations with Histology

The only training dataset in the world pairing PS-OCT signals with histological ground truth.

Clinical Validation

What leading electrophysiologists are saying.

Published in Europace. Presented at AFS Boston 2025.

Principal Investigator of the AblaView® first-in-human study. Presented the 100% durable PFA specificity result at the AF Symposium, January 2025. Lead author on the peer-reviewed Europace publication, February 2025.

Prof. Atul Verma, MD

Director of Cardiology, McGill University Health Centre. 300+ peer-reviewed publications including NEJM. Led STAR AF II.

Pioneered remote magnetic navigation and performed the first fully remote catheter ablation globally in 2003. Research lead in EP at Royal Brompton with 200+ publications. Clinical advisor on the AblaView® first-in-human study.

Prof. Sabine Ernst, MD, PhD

Professor of Practice, Imperial College London / Royal Brompton Hospital.

Lead author on the AblaView® PS-OCR preclinical study published in Circulation, 2024. Directs the Preclinical Cardiovascular Lab at Sunnybrook. Specialist in preclinical evaluation of novel ablation devices.

Dr. Maria Terricabras, MD

Cardiac EP and Director, Preclinical Cardiovascular Lab, Sunnybrook / University of Toronto.

See the evidence. Explore the system.

Dive deeper into the science and the data behind AblaView®.

See the Technology View Clinical Data